A report by Grand View Research highlights a projected compound annual growth rate (CAGR) of 10.1% for the irritable bowel syndrome (IBS) market from 2019 through to 2026.
This would see the market grow to be worth $3.3bn (€2.96bn) in the same time period, with the report noting that the increased use of Linzess/Constella (linaclotide) and Amitiza (lubiprostone) had seen a related growth in sales across the space.
All of the most common forms of treatments for IBS are small molecule therapies, including Lotronex (alosetron), Viberzi (eluxadoline), and Xifaxan (rifaximin), in addition to Linzess and Amitiza.
The report notes that the adoption of these latter two leading treatments continues to develop, in countries such as the US, UK, Germany, and Japan.
The largest revenue-generating region in 2018 was North America, followed by Europe – though the report identifies that the European region is the fastest growing.
Global prevalence of IBS is estimated to range between 10-15%, with the majority of patients being under 50 years of age and the condition disproportionately affecting women.
There were an estimated 766 million cases of IBS in those aged 15 and over globally in 2017, with this expected to develop to number 843 million by 2026.
According to an additional report, there were 21 licensing and assets acquisition deals involving IBS treatments between 2013 and 2018, as companies look to target the growing market.
The largest of such deals saw Allergan enter into a licensing agreement with Assembly Biosciences for microbiome gastrointestinal development programs in 2017. The upfront fee for the deal represented a figure of $50m but, when potential milestone payments are included, this could rise to as high as $2.8bn.